As of 2026-03-15, the EV/EBITDA ratio of agilon health Inc (AGL) is -0.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. AGL's latest enterprise value is 110.02 mil USD. AGL's TTM EBITDA according to its financial statements is -330.94 mil USD. Dividing these 2 quantities gives us the above AGL EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 12.4x | 11.8x |
| Forward P/E multiples | 10.3x - 12.8x | 11.8x |
| Fair Price | (8.03) - (9.53) | (9.04) |
| Upside | -1438.5% - -1688.6% | -1607.5% |
| Date | EV/EBITDA |
| 2026-03-13 | -0.33 |
| 2026-03-12 | -0.34 |
| 2026-03-11 | -0.38 |
| 2026-03-10 | -0.31 |
| 2026-03-09 | -0.33 |
| 2026-03-06 | -0.33 |
| 2026-03-05 | -0.41 |
| 2026-03-04 | -0.46 |
| 2026-03-03 | -0.29 |
| 2026-03-02 | -0.35 |
| 2026-02-27 | -0.32 |
| 2026-02-26 | -0.33 |
| 2026-02-25 | -0.21 |
| 2026-02-24 | -0.07 |
| 2026-02-23 | -0.12 |
| 2026-02-20 | -0.13 |
| 2026-02-19 | -0.09 |
| 2026-02-18 | -0.05 |
| 2026-02-17 | -0.02 |
| 2026-02-13 | -0.03 |
| 2026-02-12 | -0.04 |
| 2026-02-11 | -0.06 |
| 2026-02-10 | -0.15 |
| 2026-02-09 | -0.35 |
| 2026-02-06 | -0.39 |
| 2026-02-05 | -0.37 |
| 2026-02-04 | -0.44 |
| 2026-02-03 | -0.54 |
| 2026-02-02 | -0.62 |
| 2026-01-30 | -0.62 |
| 2026-01-29 | -0.66 |
| 2026-01-28 | -0.61 |
| 2026-01-27 | -0.65 |
| 2026-01-26 | -0.77 |
| 2026-01-23 | -0.82 |
| 2026-01-22 | -0.85 |
| 2026-01-21 | -0.77 |
| 2026-01-20 | -0.80 |
| 2026-01-16 | -0.86 |
| 2026-01-15 | -0.86 |
| 2026-01-14 | -0.79 |
| 2026-01-13 | -0.77 |
| 2026-01-12 | -0.82 |
| 2026-01-09 | -0.82 |
| 2026-01-08 | -0.71 |
| 2026-01-07 | -0.56 |
| 2026-01-06 | -0.60 |
| 2026-01-05 | -0.45 |
| 2026-01-02 | -0.42 |
| 2025-12-31 | -0.44 |